Abbott Laboratories (ABT) reported Q2 adjusted earnings and sales that exceeded analyst expectations, coupled with a slight increase in full-year adjusted earnings guidance. This positive news, following a significant year-to-date decline in the stock, led to its largest single-day advance in trading history.
Abbott Laboratories experienced its best single-day stock performance since 1968, jumping 13.6% after reporting Q2 adjusted earnings of $1.31 per share (vs. $1.28 consensus) and sales of $12.59 billion (vs. $12.5 billion estimates). The company also raised its full-year adjusted earnings guidance slightly. This positive reaction is particularly significant because ABT shares were down 30% year-to-date prior to this announcement, indicating that the market had set a very low bar. The strong performance suggests a potential short-term reversal in sentiment for the stock, although it still trades 30% below its December 2021 peak. For traders, this presents an opportunity to capitalize on the renewed positive momentum, but long-term investors will be watching if this marks a sustained recovery or just a relief rally.